(NASDAQ: GNLX) Genelux's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41.92%.
Genelux's earnings in 2025 is -$29,511,000.On average, 8 Wall Street analysts forecast GNLX's earnings for 2025 to be -$33,486,010, with the lowest GNLX earnings forecast at -$35,870,860, and the highest GNLX earnings forecast at -$32,489,807. On average, 7 Wall Street analysts forecast GNLX's earnings for 2026 to be -$37,817,984, with the lowest GNLX earnings forecast at -$37,719,873, and the highest GNLX earnings forecast at -$37,244,412.
In 2027, GNLX is forecast to generate -$34,384,102 in earnings, with the lowest earnings forecast at -$40,308,492 and the highest earnings forecast at -$31,301,155.